Impact of peripheral elimination on the concentration-effect relationship of remifentanil in anaesthetized dogs

British Journal of Anaesthesia

Volumn 94, Issue 3, 2005, Pages 357-365

  Kabbaj, M ^a   Vachon, P ^a   Varin, France ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Model, dog; Pharmacodynamics; Pharmacokinetics, remifentanil

Indexed keywords

PENTOBARBITAL; REMIFENTANIL;

ANESTHESIA; ANESTHESIA INDUCTION; ANIMAL EXPERIMENT; ARTERIAL BLOOD; ARTERY CATHETERIZATION; ARTICLE; BLOOD SAMPLING; COMPARTMENT MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; ELECTROENCEPHALOGRAM; NONHUMAN; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; STEADY STATE; VEIN CATHETERIZATION; VENOUS BLOOD;

EID: 14844353913     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/aei058     Document Type: Article

References (28)

1. Feldman PL, James MK, Brackeen MF, et al. Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgetics. J Med Chem 1991; 34: 2202-8
2. Dershwitz M, Hoke JF, Rosow CE, et al. Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. Anesthesiology 1996; 84: 812-20
3. Westmoreland CL, Hoke JF, Sebel PS, Hug CC jr, Muir KT. Pharmacokinetics of remifentanil (G187084B) and its major metabolite (G190291) in patients undergoing elective inpatient surgery. Anesthesiology 1993; 79: 893-903
4. Chism JP, Rickert DE. The pharmacokinetics and extra-hepatic clearance of remifentanil, a short acting opioid agonist, in male beagle dogs during constant rate infusions. Drug Metab Dispos 1996; 24 34-40
5. Chiou WL. The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part 1). Clin Pharmacokinet 1989; 17: 175-99
6. Chiou WL. The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part II). Clin Pharmacokinet 1989; 17: 275-90
7. Fuseau E, Sheiner LB. Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model. Clin Pharmacol Ther 1984; 35: 733-41
8. Segre G. Kinetics of interaction between drugs and biological systems. Farmaco (Sci) 1968; 23: 907-18
9. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979; 25: 358-71
10. Veng-Pedersen P, Gillespie WR. Single pass mean residence time in peripheral tissues: a distribution parameter intrinsic to the tissue affinity of a drug. J Pharm Sci 1986; 75: 1119-26
11. Verotta D, Beal SL, Sheiner LB. Semiparametric approach to pharmacokinetic-pharmacodynamic data. Am J Physiol 1989; 256: R1005-10
12. Donati F, Varin F, Ducharme J, Gill SS, Theoret Y, Bevan DR. Pharmacokinetics and pharmacodynamics of atracurium obtained with arterial and venous blood samples. Clin Pharmacol Ther 1991; 49 515-22
13. Hermann DJ, Egan TD, Muir KT. Influence of arteriovenous sampling on remifentanil pharmacokinetics and pharmacodynamics. Clin Pharmocal Ther 1999; 65: 511-8
14. Kabbaj M, Varin F. Simultaneous solid-phase extraction with liquid chromatography with ultraviolet absorbance for the determination of remifentanil and its metabolite in dog plasma. J Chromatogr B Biomed Sci Appl 2003; 783: 103-9
15. Holmberg L, Odar-Cederlof I, Nilsson JL, Ehrnebo M, Boreus LO. Pethidine binding to blood cells and plasma proteins in old and young subjects. Eur J Clin Pharmacol 1982; 23: 457-61
16. Grosse CM, Davis IM, Arrendale RF, Jersey J, Amin J. Determination of remifentanil in human blood by liquid-liquid extraction and capillary GC-HRMS-SIM using a deuterated internal standard. J Pharm Biomed Anal 1994; 12: 195-203
17. Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981; 6: 429-53
18. Colburn WA. Simultaneous pharmacokinetic and pharmacodynamic modeling. J Pharmacokinet Biopharm 1981; 9: 367-88
19. Wauquier A, Van den Broeck WAE, Niemgeers CJE, Janssen PAJ. Effects of morphine, fentanyl, sufentanil, and the short-acting morphine-like analgesic alfentanil on the EEG in dogs. Drug Dev Res 1981; 1: 167-79
20. Hoke JF, Cunningham F, James MK, Muir KT, Hoffman WE. Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. J Pharmacol Exp Ther 1997; 281: 226-32
21. Cox EH, Langemeijer MW, Gubbens-Stibbe JM, Muir KT, Danhof M. The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. Anesthesiology 1999; 90: 535-44
22. Haidar SH, Moreton JE, Liang Z, Hokef, Muir KT, Eddington ND. The pharmacokinetics and electroencephalogram response of remifentanil alone and in combination with esmolol in the rat. Pharm Res 1997; 14: 1817-23
23. Egan TD, Minto CF, Hermann DJ, Barr J, Muir KT, Shafer SL. Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. Anesthesiology 1996; 84: 821-33
24. Minto CF, Schnider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology 1997; 86: 10-23
25. Mandema JW, Danhof M. Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs. Clin Pharmacokinet 1992; 23: 191-215
26. Viby-Mogensen J, Ostergaard D, Donati F, et al. Pharmacokinetic studies of neuromuscular blocking agents: good clinical research practice (GCRP). Acta Anaesthesiol Scand 2000; 44: 1169-90
27. Laurin J, Donati F, Nekka F, Varin F. Peripheral link model as an alternative for pharmacokinetic-pharmacodynamic modeling of drugs having a very short elimination half-life. J Pharmacokinet Biopharm 2001; 28: 7-25
28. Mather LE. Anatomical-physiological approaches in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2001; 40: 707-22